Go to the top

Clinical Trials – Treatments for Stroke

Dr. Lopes participates in the following clinical trials that explore treatments for stroke.

For more information about these trials, please call our Research Coordinator at 312-942-1489.

IschemicStroke_3D.jpg

Penumbra Separatorâ„¢ 3D

A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke

This is a prospective, randomized, concurrent controlled, multi-center study.

SolitaireDevice

Solitaireâ„¢ FR Revascularization Device

Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (>3mm in diameter) occlusion in the cerebral circulation will be assigned to either the Penumbra System with the Separator 3D or the Penumbra System without the Separator 3D.

Each treated patient will be followed and assessed for 3 months after randomization.

Read more at clinicaltrials.gov.

Solitaire FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME)

This study is to determine if patients experiencing an Acute Ischemic Stroke due to large vessel occlusion, treated with combined IV t-PA and Solitaire FR within 6 hours of symptom onset have less stroke-related disability than those patients treated with IV t-PA along. Read more at clinicaltrials.gov.

POSITIVE: PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy

The primary objective of this randomized trial is to determine the safety and efficacy of intra-arterial reperfusion in Acute Ischemic Stroke (AIS) patients ineligible for IV-tPA as selected by physiologic imaging criteria. Read more at clinicaltrials.gov.

Post Market Surveillance Study of the Wingspan Stent System (WEAVE)

The primary objective of this study is to evaluate the rate of stroke and/or death in patients treated with the Wingspan Stent System, according to the Indications for Use, within 72 hours post procedure. Read more at clinicaltrials.gov.